logo-loader
CytoDyn

Full interview: CytoDyn moving towards Phase 2 trial to treat NASH with flagship leronlimab drug

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech has filed an Investigational New Drug (IND) application and a Phase 2 clinical trial protocol with the FDA for its flagship drug leronlimab to treat patients with non-alcoholic steatohepatitis (NASH).

Pourhassan says because the company has positive pre-clinical data, with zero-drug related adverse effects, the company can file to skip Phase 1 and go straight to Phase 2.

Quick facts: CytoDyn

Price: $0.39

Market: OTCQB
Market Cap: $146.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn CEO discusses findings in Yale University report,...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive that scientists at Yale University's Office of Cooperative Research have recently published a report detailing its successful demonstration of the efficacy of monoclonal antibody targeting of CCR5. Pourhassan says CytoDyn has the...

3 days, 18 hours ago

2 min read